Roberto M. Lemoli

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat et al. · New England Journal of Medicine · 2020 · 2.8K citations · Full text

Medicine, Pharmacotherapy, Medical Oncology +3

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Chiara Cattaneo, Luca Arcaini et al. · The Lancet Haematology · 2020 · 554 citations · Full text

Medicine, Hematology, Oncology +16

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6

Marina Ratta, Francesco Fagnoni, Antonio Curti et al. · Blood · 2002 · 447 citations · Full text

Life Sciences, Cell Biology, Immunology +13

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

Antonio Curti, Loredana Ruggeri, Alessandra D’Addio et al. · Blood · 2011 · 402 citations · Full text

Life Sciences, Hematology, Immunology +16